The Predictive Value of Semi-quantitative Index of99mTc-3PRGD2 SPECT/CTfor Patients with HER2 Positive Breast Cancer

被引：0
|
作者：
Liu, Haiyan [1 ]
Li, Wanting [1 ]
Cui, Yongping [4 ]
Qin, Lijun [1 ,5 ]
Wu, Zhifang [1 ,3 ]
Ren, Yuan [5 ]
Liu, Jing [2 ]
Zhang, Guochen [6 ]
Hu, Guang [1 ,3 ]
Wang, Hongliang [1 ,3 ]
Cui, Yali [1 ]
Niu, Jing [1 ]
Li, Sijin [1 ,3 ]
机构：
[1] Shanxi Med Univ, Hosp 1, Taiyuan, Shanxi, Peoples R China
[2] Shanxi Med Univ, Hosp 1, Dept Gen Surg, Taiyuan, Shanxi, Peoples R China
[3] Shanxi Med Univ, Mol Imaging Precis Med Collaborat Innovat, Taiyuan, Shanxi, Peoples R China
[4] Shanxi Med Univ, Translat Med Res Ctr, Taiyuan, Shanxi, Peoples R China
[5] Shanxi Med Univ, Tumor Hosp, Taiyuan, Shanxi, Peoples R China
[6] Shanxi Med Univ, Tumor Hosp, Dept Breast Surg, Taiyuan, Shanxi, Peoples R China
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1367
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    MODERN PATHOLOGY, 2019, 32
  • [22] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2019, 99
  • [23] 99mTc-HPArk2 SPECT/CT in the evaluation of HER2-positive breast cancer: a pilot prospective study
    Wang, Rongxi
    Zhou, Yidong
    Du, Shuaifan
    Shi, Jiyun
    Zhu, Zhaohui
    Wang, Fan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [24] Evaluation of 99mTc-3PRGD2 SPECT imaging on angiogenesis in animal models of lung cancer
    Wu, Yongkun
    Wang, Yufei
    Yang, Zheng
    Teng, Chuanhui
    Guo, Zhanlin
    THORACIC CANCER, 2022, 13 (21) : 3025 - 3031
  • [25] 99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer
    Bin Ji
    Bin Chen
    Ting Wang
    Yan Song
    Minglong Chen
    Tiefeng Ji
    Xueju Wang
    Shi Gao
    Qingjie Ma
    European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42 : 1362 - 1370
  • [26] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [27] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Kurebayashi, Junichi
    Kanomata, Naoki
    Yamashita, Tetsumasa
    Shimo, Toshiro
    Mizutoh, Akiko
    Moriya, Takuya
    Sonoo, Hiroshi
    BREAST CANCER, 2015, 22 (03) : 292 - 299
  • [28] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [29] Locoregional recurrence in patients with HER2 positive breast cancer
    Brollo, Janaina
    Kneubil, Maximiliano Cassilha
    Botteri, Edoardo
    Rotmensz, Nicole
    Duso, Bruno Achutti
    Fumagalli, Luca
    Locatelli, Marzia Adelia
    Criscitiello, Carmen
    Lohsiriwat, Visnu
    Goldhirsch, Aron
    Leonardi, Maria Cristina
    Orecchia, Roberto
    Curigliano, Giuseppe
    BREAST, 2013, 22 (05): : 856 - 862
  • [30] THE UPFRONT THERAPY FOR HER2 POSITIVE BREAST CANCER PATIENTS
    Iwata, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 76 - 76
12345